2019 Letter to Shareholders
Halozyme is a biotechnology company focused on novel biological and drug delivery approaches. Our goal is to bring innovative and disruptive solutions that improve the patient experience and, potentially patient outcomes, when our technology is combined with established or emerging treatments.
Our proprietary enzyme rHuPH20 is used to facilitate the delivery of injected drugs and fluids and potentially reduce the treatment burden of other drugs to patients and forms the basis of our ENHANZE® drug delivery technology.
Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies, including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx.
Halozyme derives revenues from these collaborations in the form of milestone payments and royalties as the company's partners make progress developing and commercializing their products with ENHANZE®.
Five products have received regulatory approvals in the United States and/or Global Markets as subcutaneous products utilizing ENHANZE® and are marketed by the following companies:
- Phesgo™(pertuzumab and trastuzumab): Roche
- Darzalex FASPRO™(daratumumab and hyaluronidase – fihj): Janssen
- Herceptin®(trastuzumab): Roche. Marketed as Herceptin HylectaTM SC (trastuzumab and hyaluronidose-oysk) (US) and Herceptin® SC (trastuzumab subcutaneous) in Europe
- Rituxan®/MabThera®(rituximab): Roche. Marketed as RITUXAN HYCELATM (rituximab/hyaluronidase human) (US) and MabThera® SC (rituximab subcutaneous) (EU)
- HYQVIA® (Immune Globulin Infusion 10%): Takeda
One additional subcutaneous product candidate utilizing ENHANZE® is currently under FDA and EMA review:
- Darzalex®(daratumumab): Janssen (JNJ)
In addition, we market and commercialize Hylenex® recombinant (hyaluronidase human injection) in the United States, which is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs.
Halozyme is based in San Diego. We have approximately 130 employees.